Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration ...

At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for ...

At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global ...

Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of global harmonization and streamlining biosimilar development during a panel ...

At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen ...